Zai Lab Ltd
Povetacicept
IgAN
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for Povetacicept in IgAN are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026”